Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less-Reference-Cited by-同舟云学术

Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less

Published:2019-04-16 Issue:6 Volume:34 Page:812-815
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord

Author:

Olanow C. Warren

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.27690

Reference43 articles.

1. Levodopa in the treatment of Parkinson's disease: Current controversies

2. Levodopa and the Progression of Parkinson's Disease

3. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease

4. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6‐hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro;Graham DG;Mol Pharmacol,1978

5. Oxidation reactions in Parkinson's disease;Olanow CW;Neurology,1990

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HucMSC extracellular vesicles increasing SATB 1 to activate the Wnt/β‐catenin pathway in 6‐OHDA‐induced Parkinson's disease model;IUBMB Life;2024-07-31

2. Flexible Wearable Electrochemical Sensors Based on AuNR/PEDOT:PSS for Simultaneous Monitoring of Levodopa and Uric Acid in Sweat;ACS Sensors;2024-06-03

3. Sublingual apomorphine in the treatment of Parkinson’s disease;Journal of Neural Transmission;2024-05-14

4. The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology;International Journal of Molecular Sciences;2024-04-15

5. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study;Journal of Neurology;2024-03-28